
Alphabet owned Google’s $2.1 billion bid for fitness trackers company Fitbit could pose privacy risks, the European Data Protection Board warned on Thursday, adding its voice to other critics of the deal.
Google announced the deal in November last year, as it seeks to compete with Apple and Samsung in the crowded market for fitness trackers and smart watches.
Fitbit, whose fitness trackers and other devices monitor users’ daily steps, calories burned and distance travelled, would give the US tech giant access to a trove of health data gathered from Fitbit devices.
“The possible further combination and accumulation of sensitive personal data regarding people in Europe by a major tech company could entail a high level of risk to privacy and data protection,” it said.
It urged the companies to assess their data privacy requirements and privacy implications in a transparent way and mitigate possible privacy and data protection risks before seeking EU antitrust approval for the deal.
Google said it would never sell personal information to anyone and that Fitbit health and wellness data would not be used for its ads while Fitbit users would have the option to review or delete their data.
“Protecting peoples’ information is core to what we do, and we will continue to work constructively with regulators to answer their questions,” the company said in a statement.
European Competition Commissioner Margrethe Vestager, who will vet the deal, in November voiced her concerns about big companies targeting data-heavy rivals.
The European Commission on Thursday in an emailed comment said it had yet to be formally notified.
Full Content: CNBC
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Meta Begins Defense After FTC Concludes Case in Landmark Antitrust Trial
May 15, 2025 by
CPI
UK Data Bill Still No Closer to Passage As Parliamentary ‘Ping-Pong’ Drags On
May 15, 2025 by
CPI
Regeneron Pharmaceuticals Awarded $271.2M in Damages Against Amgen
May 15, 2025 by
CPI
FTC Chair Proposes 15% Staff Reduction Amid Budget Constraints
May 15, 2025 by
CPI
UK Urges Antitrust Watchdog to Prioritize Growth and Clarity in Business Regulation
May 15, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas